Gold-based cancer therapy could face competition from other substances

gold based cancer therapy could face competition from other substances

Sumary of Gold-based cancer therapy could face competition from other substances:

  • Researchers at Karolinska Institutet in Sweden now show that other molecules that inhibit the same biological system have a more specific effect than auranofin and therefore may have greater potential as cancer therapies.
  • “There’s a great deal of interest in the ability to inhibit the thioredoxin system in the treatment of cancer, but there’s a risk that healthy cells will also be damaged and killed,” says the study’s co-last author Elias Arnér, professor at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet.
  • ” The researchers studied the effects of AF in mouse cancer cells (lung adenocarcinoma and melanoma) and compared them with other TrxR-inhibiting molecules called TRi-1 and TRi-2 (thioredoxin reductase inhibitors 1 and 2).
  • TRi-1 and TRi-2 have recently been developed by Elias Arnér’s research group and shown anticancer effects in mouse models.
  • They also show that TRi-1 seems to be the most specific TrxR inhibitor described to date.
  • “Our results can serve as an important blueprint for further studies of AF’s mechanism of action and side effects,” says the study’s other co-last author Roman Zubarev, professor at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close